1,090 search results for “drugs” in the Public website
-
Prediction of brain target site concentrations on the basis of CSF PK: impact of mechanisms of blood-to-brain transport and within brain distribution
Promotor: Prof.dr. M. Danhof, Co-promotor: E.C.M. de Lange
-
BioTherapeutics (MSc)
The master’s specialisation BioTherapeutics at Leiden University is a two-year programme which trains students in research in specific drug delivery techniques. The programme also examines the development of new therapeutic approaches to treat immune-based disorders, such as atherosclerosis, metabolic…
-
Oncode Accelerator
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Contact
Division contact information & address
-
New techniques for tuberculosis treatment
About nine million people worldwide contract tuberculosis each year. Research into new treatment for this disease has received fresh stimulus with more efficient techniques and a new understanding of how the tuberculosis bacteria works.
-
Systems Biomedicine and Pharmacology (MSc)
The two-years master’s specialisation System Biomedicine and Pharmacology at Leiden university focuses on predicting drug response with computational modelling, developing individualised therapies, and developing innovative analytical tools for personalised health strategies.
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Dosing considerations for preterm neonates: from pharmacometrics to clinical practice
Prematurely born neonates require, amongst others, pharmaceutical therapy. Dosing guidelines for these therapies are often based on data from term born neonates or older infants, while these are not necessarily similar to prematurely born neonates.
-
Allosteric modulation and ligand binding kinetics at the Kv11.1 channel
Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman
-
Strategy
The division of BioTherapeutics consists of the former divisions Biopharmaceutics and Drug Delivery Technology.
- Research
-
Coiled-coil biomaterials for biological applications
This dissertation contains four works during my PhD. Different biomaterials have been designed based on coiled-coil peptides. These biomaterials have a range of applications, inclusing drug delivery, cell sorting to cell-cell fusion.
-
Quantitative Clinical Pharmacology
The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…
-
Research
Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…
-
Education
Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.
-
Development of hyaluronan-based dissolving microneedle arrays for dermal vaccination
Dissolving microneedles are a subgroup of microneedle types that completely dissolve within the skin. During this dissolving process the vaccine, stored in the needle matrix, is released into the skin.
-
History
Life Sciences Artificial Intelligence Data Science
- GTGC lunch seminar: Santino Regilme on Global Drug Wars
-
Bio-Pharmaceutical Sciences (BSc)
As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
Cannabinoid receptor 2 as a ‘drugable’ target: kinetic profile of novel receptor ligands
Supervisor: Andrea Martella
-
Novel analytical approaches to characterize particles in biopharmaceuticals
Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
Chemokine signaling in Tuberculosis and Salmonella infection
Who benefits from CXCR/CXCL chemokine signaling during infection: host or pathogen?
-
Cancer cells: A closer look
What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.
-
Key publications
Key publications of the Antiviral Pharmacology group.
-
Prediction of human gut (colon cancer) target site concentrations and PKPD relationships
The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.
-
Quantitative pharmacology of antimicrobials
Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.
-
NACTAR: The lugdunomycins: a new class of polyketide antibiotics with unique chemical scaffold
Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.
-
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474, SCIENCE, 2017
The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered…
-
Exploration of the endocannabinoid system using metabolomics
To increase clinical success rate of drugs, a better understanding of drug action mechanism and disease dynamics is required. Metabolomics, which studies small molecules involved in biochemical processes in organisms, has shown to be a useful tool for this better understanding.
-
Amphiphilic miktoarm star copolymers
Within this project, PeptoMiktoStars were realized through an orthogonal protecting group strategy and should be investigated further regarding their potential as drug delivery systems in the field of drug delivery to inflamed areas in cancer, bacterial infections or autoimmune diseases.
-
First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children
Growth and development affect the metabolism of drugs administered to neonates, infants, and children.
-
LED3 PhD-Postdoc Symposium 2024
Conference
-
Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome
Fungal infections pose a significant threat to individuals with compromised immune systems and despite advancements in diagnosis and treatment, they continue to jeopardize patient’s health.
-
Previous Winners
On this page you can learn more about the history of our Faculty Awards and view the previous winners.
-
Two-pronged attack on infectious diseases
A combination of two potential drugs gives hope of a 'super blockage' of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.
-
Cancer research focusing on quality of life
Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…
-
Hit and Lead Optimization
The goal of hit and lead optimization is to optimize suitable chemical starting points that can modulate a drug target. The methods and technologies used are similar to those in Hit Discovery, but once the compound has shown activity in an animal model, it moves from 'hit' to 'lead.'
-
Bone and joint disorders: Screening and early clinical drug development
PhD defence
-
Using AI to improve the Design-Make-Test cycle with Galapagos
Researchers at LED3 are working together with biopharmaceutical company Galapagos to develop software for use in early drug discovery (funded by NWO). This software is able to design molecules with several simultaneously optimized characteristics and will also take prediction reliability into consideration…
-
Covalent inhibitors of G protein-coupled receptors: the case of adenosine receptors
Supervisor: Xue Yang
-
Physicochemical analysis of allosteric binding pockets
Supervisor: Gerard van Westen
-
Polypept(o)ide-based nanostructures for therapeutic and diagnostic application
Nanoparticles exhibit a number of adjustable properties, e.g., their size, shape, and surface and core chemistry, which can be further diversified with different functional moieties. This opens a broad field for application in diagnostic and therapy. In this respect, the use of a polymeric hybrid material,…
-
Partner Institutes
The IBL represents the core of modern biological research at Leiden and we interact closely with the other life science Partner Institutes in the faculty:
-
New resource for the modelling community
The Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This publically available open-access resource will make it easier for researchers…
-
Researchers reveal how stem cells make decisions
Embryonic stem cells have the remarkable ability to develop into any type of cell. On their way to become for example a liver or a heart cell, they must repeatedly decide between alternative developmental paths. How they make these decisions is largely unknown. An international team of biophysicists…
-
Laura Heitman nominated for Prix Galien
Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.